A Phase 3 interventional study of Dapirolizumab pegol in Systemic Lupus Erythematosus, sponsored by UCB Biopharma SRL. Enrolling by invitation at 123 sites in 24 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Lupus Erythematosus, Systemic by UCB S.A. — 4 open to participants now, 4 under way, 2 of them phase 3. Lupus Erythematosus, Systemic · UCB S.A..
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., this one is the 4th largest by planned enrollment, is the only one that started in 2021, is one of 9 in phase 3, and was the 18th registered.
1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.
Browse Lupus Erythematosus, Systemic studies →4 of the 21 studies in Lupus Erythematosus, Systemic by UCB S.A. are open now, in 12 countries. Recruiting first, the newest first:
Candid Therapeutics · Sites in China
Ages 18–75
UCB Biopharma SRL · Sites in United States, Argentina, Belgium and 20 more countries
Ages 16+
UCB Biopharma SRL
Ages 18–45 · Women only
By country, each count listing its studies:
Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 7 · Phase 3 9
First in 2005; this study’s year is marked. 1 started in 2021.
This study's planned enrollment of 760 is above the median of 52 across 878 interventional studies indexed under Lupus Erythematosus, Systemic.
Median enrollment 54 across the 21 interventional studies. Of the 16 that completed or were terminated, 5 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 21 studies in Lupus Erythematosus, Systemic by UCB S.A., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Study participant has any medical or psychiatric condition (including conditions due to neuropsychiatric systemic lupus erythematosus (SLE)) that, in the opinion of the Investigator, could jeopardize or would compromise the study participant's ability to participate in this study. This includes study participants with a life-threatening condition or ongoing at the start of the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive dapriolizumab pegol throughout the Treatment Period.
Drug: Dapirolizumab pegol
Subjects will receive dapirolizumab pegol at prespecified time-points.
Also known as: DZP, CDP7657
Incidence of treatment-emergent adverse events (TEAEs) during the study
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, whether or not these events are related to study treatment.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of serious treatment-emergent adverse events during the study
A serious treatment-emergent adverse event (serious TEAE) is any untoward medical occurrence that at any dose: * Results in death * Is life-threatening * Requires in patient hospitalisation or prolongation of existing hospitalisation * Results in persistent disability/incapacity * Is a congenital anomaly or birth defect * Other important medical events which based on medical or scientific judgement may jeopardise the patients, or may require medical or surgical intervention to prevent any of the above
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuation
Treatment-emergent adverse events (TEAEs) are any untoward medical incidence in a subject during administered study treatment, and leading to permanent drug discontinuation whether or not these events are related to study treatment.
Time frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 24
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
Time frame: Week 24
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 48
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
Time frame: Week 48
Achievement of prevention of severe BILAG flares (severe BILAG flare-free) through Week 104
BILAG severe flare is defined as a new British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) Grade A in any system due to individual items that are new or worse qualifying for the Grade A (Isenberg et al, 2011). Determination of items that are new or worse qualifying for the Grade A will be according to the supplementary information for the numerical scoring of the BILAG-2004 index (Yee et al, 2010).
Time frame: Week 104
Achievement of LLDAS at Week 48
Low lupus disease activity state (LLDAS) is defined as: * No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit * PGA ≤33 mm * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Time frame: Week 48
Achievement of LLDAS at Week 104
Low lupus disease activity state (LLDAS) is defined as: * No significant disease activity as per SLEDAI-2K (SLEDAI-2K score ≤4 with no activity in major organ systems (renal, central nervous system (CNS), cardiopulmonary, vasculitis, fever) * No new and/or worsening disease activity defined as no SLEDAI-2K component documented as present that was not documented present at previous visit * PGA ≤33 mm * Prednisone equivalent systemic dose for systemic lupus erythematosus (SLE) indication ≤7.5 mg per day * Stable standard maintenance doses of immunosuppressive drugs as allowed by protocol
Time frame: Week 104
Achievement of BICLA response at Week 48 (using the parent study baseline as the reference point)
A study participant is considered to be a BILAG 2004-based Composite Lupus Assessment (BICLA) responder if all of the following is fulfilled: 1. British Isles Lupus Assessment Group Disease Activity Index 2004 (BILAG 2004) improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and 2. No worsening in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and 3. No worsening in the Physician's Global Assessment of Disease (PGA) compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale
Time frame: Week 48
Achievement of BICLA response at Week 104 (using the parent study baseline as the reference point)
A study participant is considered to be a BICLA responder if all of the following is fulfilled: 1. BILAG 2004 improvement without worsening (A scores at Baseline improved to B, C or D; B scores improved to C or D; no new A scores and ≤1 new B.); and 2. No worsening in the SLEDAI-2K total score compared to Baseline Visit (defined as no increase in SLEDAI-2K total score); and 3. No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale
Time frame: Week 104
Achievement of SRI-4 response at Week 48 (using the parent study baseline as the reference point)
The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met): * Reduction in SLEDAI-2K score of ≥4 * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline * No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.
Time frame: Week 48
Achievement of SRI-4 response at Week 104 (using the parent study baseline as the reference point)
The Systemic Lupus Erythematosus Responder Index-4 (SRI 4) define responders as (ie, all criteria must be met): * Reduction in SLEDAI-2K score of ≥4 * No shift from BILAG 2004 Grade B, C, D, or E to A post-Baseline * No more than 1 shift from BILAG 2004 Grade C, D, or E to B post-Baseline * No worsening in the PGA compared to Baseline Visit defined as ≤10 mm increase on a 100 mm visual analog scale.
Time frame: Week 104
Change from parent study Baseline in FATIGUE-PRO Total score at Week 48
The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.
Time frame: From Baseline to Week 48
Change from parent study Baseline in FATIGUE-PRO Total score at Week 104
The FATIGUE-PRO (Fatigue patient-reported outcome) is a PRO instrument measuring fatigue, a core symptom of SLE, developed using qualitative and quantitative research conducted in patients with SLE. It is composed of 31 items covering 3 domains: Physical Fatigue (items 1-9), Mental and Cognitive Fatigue (items 10-20), and Susceptibility to Fatigue (items 21-31). The study participant is asked to score each fatigue item based on how frequently they experienced the item during the past 7 days using the following response options: 1=none of the time; 2=a little of the time; 3=some of the time; 4=most of the time; 5=all of the time. Responses to the FATIGUE PRO questions allow calculation of 4 scores: a Total score assessing overall fatigue and a score for each of the 3 domains, all ranging from 0 to 100, with higher scores indicating higher levels of fatigue.
Time frame: From Baseline to Week 104
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 48
The achievement of a reduction in glucocorticoid dose from \>7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 48
Time frame: From Baseline to Week 48
Percentage of participants having a reduction in glucocorticoid dose from >7.5mg/day prednisone-equivalent dose at the parent study Baseline to ≤7.5mg/day at Week 104
The achievement of a reduction in glucocorticoid dose from \>7.5mg/day prednisone equivalent dose at the parent study Baseline to ≤7.5mg/day prednisone equivalent at Week 104
Time frame: From Baseline to Week 104
Showing the first 100 of 123 sites across 24 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Aug 2030, 108 months after the start.
Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's planned 108 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dapirolizumab pegol
Lupus Erythematosus, Systemic →